339362-68-4 Usage
Uses
Used in Organic Synthesis:
3-Aminocyclopentanone is utilized as a key intermediate for the preparation of various heterocyclic compounds and pharmaceuticals, underpinning its importance in the development of new drugs and organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-aminocyclopentanone is employed as a versatile building block, contributing to the synthesis of complex organic molecules that can be further utilized in the creation of novel therapeutic agents.
Used in Material Science:
3-Aminocyclopentanone also holds potential in material science, where it may be applied in the development of new materials, leveraging its chemical properties to enhance material characteristics or to create new composites with unique properties.
Used in Chemical Reactions:
As a component in chemical reactions, 3-aminocyclopentanone is used as a reagent for processes such as reduction, acylation, and alkylation, facilitating the synthesis of a wide array of chemical products across different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 339362-68-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,3,9,3,6 and 2 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 339362-68:
(8*3)+(7*3)+(6*9)+(5*3)+(4*6)+(3*2)+(2*6)+(1*8)=164
164 % 10 = 4
So 339362-68-4 is a valid CAS Registry Number.
339362-68-4Relevant academic research and scientific papers
Ligustrazine-fused cyclic compound and medicine composition thereof, as well as application in medicine thereof
-
, (2017/07/21)
The invention discloses a ligustrazine-fused cyclic compound and a medicine composition thereof and application in a medicine. The ligustrazine-fused cyclic compound has the following structural general formula I: as shown in the specification. The medicine composition is a medicinal active component for the ligustrazine-fused cyclic compound and a pharmaceutically acceptable carrier, an excipient, a diluent, an adjuvant, a medium or a combination thereof; the ligustrazine-fused cyclic compound and the medicine composition can be used for preventing or treating cardiovascular and cerebrovascular diseases, digestive system diseases, respiratory diseases, the alzheimer's disease, kidney diseases and complications of the above-mentioned diseases due to thrombus and excessive free radicals. The ligustrazine-fused cyclic compound disclosed by the invention has an extremely good inhibition effect on in vitro ADP (adenosine diphosphate)-induced platelet aggregation; meanwhile, compared with the pharmacokinetic property of ligustrazine serving as a female parent, the pharmacokinetic property of the ligustrazine-fused cyclic compound in the body of a rat is obviously improved.
